Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

BVS - Bioventus Inc - Ordinary Shares - Class A


IEX Last Trade
10.05
0.170   1.692%

Share volume: 427,296
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST

PREVIOUS CLOSE
CHG
CHG%

$9.88
0.17
1.72%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Company vs Stock growth
vs
Performance
5 Days
1.31%
1 Month
37.30%
3 Months
48.23%
6 Months
112.03%
1 Year
185.51%
2 Year
33.64%
Key data
Stock price
$10.05
P/E Ratio 
-15.61
DAY RANGE
N/A - $10.05
EPS 
-$0.66
52 WEEK RANGE
$2.82 - $10.26
52 WEEK CHANGE
$1.86
MARKET CAP 
655.128 M
YIELD 
N/A
SHARES OUTSTANDING 
65.187 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
BETA 
1.24
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$787,247
AVERAGE 30 VOLUME 
$843,703
Company detail
CEO:
Region: US
Website: bioventusglobal.com
Employees: 1,190
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry:
Sector:

bioventus® is a global leader in orthobiologics and its mission is to make a difference by helping patients resume and enjoy active lives. bioventus accomplishes this with its orthobiologic products for musculoskeletal healing, regeneration and related biosurgery that engage and enhance the body’s natural healing processes. the company has two product portfolios for orthobiologics, bioventus active healing therapies and bioventus surgical, which are created through a combination of internal product development, product/business acquisition, and distribution agreements. established in 2012, bioventus is privately held and headquartered in durham, nc. the company has nearly 600 employees worldwide and its international headquarters is in hoofddorp, the netherlands. bioventus also has offices in memphis, tn, australia and canada, and a research and development site is located in boston. bioventus works with patients, payers and health care providers throughout the world, and generat

Recent news